The offshoots of JN.1 in the Evolutionary Trajectory of COVID-19

While the current SARS-COV-2 viral activity levels may seem reassuring (back to the levels seen in October-November 2023), the evolving world of JN.1 offshoots, where the next generation of variants is taking shape, presents a compelling case for anticipating the potential challenges that lie ahead. 

From the widespread presence of JN.1.16 across continents to the emerging dominance of JN.1.13 in the U.S., the current variant landscape is rapidly shifting, although the potential implications for the future are not quite clear. 

The roots of the pandemic can be traced back to lineage A, with many initial sequences originating from China and subsequently spreading globally, including to regions such as South East Asia, Japan, South Korea, Australia, the USA, and Europe. Lineage B followed as the second major haplotype, with subsequent evolutions leading to the emergence of various sublineages.

In 2020, we witnessed the emergence of variants such as Alpha (B.1.1.7) and Delta (B.1.617.2).  The Omicron variant (B.1.1.529) identified in late 2021 marked a significant turning point, causing the largest peak in infectiousness in early 2022. Its major offshoots, BA.1 and BA.2, paved the way for the rise of XBB and other sublineages. Following the initial surge of the original Omicron BA.1 variant, there has been a consistent rise in cumulative infections with public health efforts seemingly playing down mitigation measures. 

In September 2023, from the less prevalent BA.2.86 lineage, a new offshoot emerged: JN.1. By late December 2023, JN.1 had become predominant, rapidly outpacing other variants to account for a substantial proportion of SARS-CoV-2 infections globally. With over 30 mutations in the spike protein, including the notable L455S mutation, JN.1 demonstrated heightened immune escape and infectivity, leading to its widespread dissemination. By December 25, 2021, it accounted for 58.6% of the COVID-19 cases reported in the U.S. By late December 2023, it had become predominant, rapidly outpacing other variants to account for a substantial proportion of SARS-CoV-2 infections globally. By the end of February, over 97% of variant sequences detected in US in wastewater were JN.1. With over 30 mutations in the spike protein, including the notable L455S mutation, JN.1 demonstrated heightened immune escape and infectivity, leading to its widespread dissemination. The effectiveness of infection with prior variants in preventing reinfection with JN.1 variant was estimated at 1.8% (95% CI: -9.3-12.6%), declining rapidly from 82.4% (95% CI: 40.9 to 94.7%) within 3 to less than 6 months, reaching negligible levels after one year. 

As the evolutionary trajectory of JN.1 variants continues to unfold, new designations such as JN.1.11.1.1 (BA.2.86.1.1, out of India) and JN.1.23 (S:K444R and Y453F, out of Brazil) are emerging in different geographic regions, signaling the arrival of second-generation JN.1s. 

Lineages like JN.1.4, JN.1.7, JN.1.11.1, and JN.1.13 are exhibiting strong growth patterns, with JN.1.13 accounting for almost 10% of sequences in the Northeast region of the U.S. by March, according to Nowcast estimates. JN.1.4 variant dominates in traveler based genomic surveillance (15%), followed by JN.1.18 (~9%), JN.1.1 (6.7%), JN.1.11.1 (5.87%), KP.2 (4.12%); KP.2, JN.1.7 with JN.1.13.1 comprising only 0.65% of sequences. JN.1.16 seemed to dominate among flipper seqs uploaded in February from multiple International Airports, but quickly lost its lead. JN.1.11.1 is rapidly catching up and KP.2 (now arriving from multiple countries) seems to be even more powerful. According to CovSpectrum data KP.2 (JN.1.11.1.2; BA.2.86.1.1.11.1.2) has 333% growth advantage over JN.1, while it's 200% for KP.1.1 (JN.1.11.1.1.1; BA.2.86.1.1.11.1.1.1), and only 50% for JN.1.13.1 (BA.2.86.1.1.13.1). 

JN.1 was slightly better evading immune system than previous leaders HV.1 & Eris (descendants of EG.5) , but many new lineages with enhanced immune evasion capabilities emerged since. The new KP.2 lineage of SARS-CoV-2 is showing signs of spread. It was first detected in samples collected in early January from Assam, India. It has since showed up in NZ, across North America, Europe and Asia. Multiple JN.1 branches including KP.1.1 and KP.2 harbor S:R346T+S:F456L mutations also known as FLiRT. KP.2 adds the Spike R346T mutation to JN.1.11.1. Globally, KP.2 was showing a very strong growth advantage of 14% per day (101% per week) over other Pirola variants since February. That predicts a crossover in late March. It looks like the best candidate for driving the summer wave, if one materializes.

At the 4-year mark since the WHO Pandemic Declaration, the U.S. averaged 3.5 cumulative infections per person, with a range of 2.5 to 4 (with few that still has not gotten the virus and some that had it 6-7 times or more). Probably 40-60% of transmission were asymptomatic and up to 10% were prolonged. If the current infection rate persists, it could reach an average of 7.3 infections per person in 4 years, with a range of 5.1 to 8.4.

As we navigate this new post-emergency pandemic phase, it is crucial that we continue global surveillance efforts to stay ahead of the evolving SARS-CoV-2 landscape. 



REFERENCES

Yang S, Yu Y, Xu Y, Jian F, Song W, Yisimayi A, Wang P, Wang J, Liu J, Yu L, Niu X, Wang J, Wang Y, Shao F, Jin R, Wang Y, Cao Y. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Lancet Infect Dis. 2024 Feb;24(2):e70-e72. doi: 10.1016/S1473-3099(23)00744-2. Epub 2023 Dec 15. Erratum in: Lancet Infect Dis. 2024 Jan 3;: PMID: 38109919.

Matthew E. Levy, Vanessa Chilunda, Phillip R. Heaton, Deran McKeen, Jason D. Goldman, Richard E. Davis, Cynthia A. Schandl, William B. Glen, Lisa M. McEwen, Elizabeth T. Cirulli, Dana Wyman, Andrew Dei Rossi, Hang Dai, Magnus Isaksson, Nicole L. Washington, Tracy Basler, Kevin Tsan, Jason Nguyen, Jimmy Ramirez, Efren Sandoval, William Lee, James Lu, Shishi Luo. XBB.1.5 mRNA COVID-19 Vaccination and Inpatient or Emergency Department Visits Among Adults Infected with SARS-CoV-2 JN.1 and XBB-Lineage Variants medRxiv 2024.03.05.24303796; doi: https://doi.org/10.1101/2024.03.05.24303796

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

COVID in May

Image
Concerns about a potential resurgence of COVID-19 are mounting as summer 2024 approaches.  This is driven by several indicators, including social media posts, healthcare data, and wastewater surveillance across different regions. Our study findings corroborate this trend.  While many forecasters anticipate a surge, others expect a gradual increase through the end of May, and then a decline again around early June. Reports from social media suggest emerging clusters of COVID-19 in Texas, several Canadian provinces, the UK, and on cruises in northern regions such as a Norwegian cruise to Alaska.  Data from Alberta's Respiratory virus dashboard   (total weekly laboratory-confirmed COVID-19 cases) and wastewater surveillance in Calgary indicate an uptick in COVID-19 cases starting April 2024. The most recent statistics from Alberta Health reveal a significant increase in hospitalizations due to COVID-19, with 114 individuals currently hospitalized—an increase of more than 20% over two
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral load
Read more